文献速递慢阻肺

警报素靶向生物制剂在慢阻肺治疗中的新兴作用

The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD.
PubMed 文献 · Chest · 2024-12-02

本综述聚焦慢阻肺病理生理、炎症机制及生物制剂调控这些机制的潜在应用。慢阻肺炎症反应包括1型和2型免疫细胞,部分患者存在嗜酸性粒细胞增多提示2型炎症。靶向IL-5的研究未能显著减少急性加重,提示仅调节嗜酸性粒细胞可能不足以治疗慢阻肺。基于对警报素在炎症级联中更广泛作用的理解,某些生物制剂可能使特定慢阻肺内型患者获益,正在进行的试验将提供阻断特定通路(如IL-5、IL-4/IL-13、IL-33、胸腺基质淋巴细胞生成素)哪些人群可获益的信息。

要点

  • 慢阻肺炎症涉及1型和2型免疫细胞,部分患者有嗜酸性粒细胞增多。
  • 靶向IL-5未能显著减少慢阻肺急性加重。
  • 警报素靶向生物制剂可能对特定慢阻肺内型有效。

核心结论

  • 靶向炎症通路的生物制剂可能对特定慢阻肺患者是有效治疗。

研究设计与样本

  • 本综述聚焦慢阻肺病理生理、炎症机制及生物制剂调控这些机制的潜在应用。

主要发现

  • 慢阻肺炎症反应包括1型和2型免疫细胞。
  • 相当比例慢阻肺患者存在嗜酸性粒细胞增多提示2型炎症。
  • 靶向IL-5的研究未能显著减少慢阻肺急性加重,提示仅调节嗜酸性粒细胞可能不足。
  • 基于对警报素在炎症级联中更广泛作用的理解,某些生物制剂可能使特定慢阻肺内型患者获益。
  • 正在进行的试验将提供阻断特定通路(如IL-5、IL-4/IL-13、IL-33、胸腺基质淋巴细胞生成素)哪些人群可获益的信息。

临床怎么用

  • 生物制剂可能作为特定慢阻肺患者的治疗选择,需根据内型选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC IMPORTANCE: COPD is a complex, heterogeneous lung disease characterized by persistent airflow limitation secondary to airways and parenchymal abnormalities, and respiratory symptoms, including dyspnea, fatigue, chronic cough, and sputum production. Cigarette smoke exposure is a major contributor to COPD; however, inhalation of toxic particles and other environmental and host factors can contribute to its genesis. Over time, the clinical course is frequently punctuated by exacerbations that further accelerate lung function decline and increase exacerbation risk. Despite current optimal therapy, many patients remain symptomatic, have exacerbations, and have increased morbidity, mortality, and health care costs. This review focuses on current knowledge of COPD pathophysiology, the role of inflammatory mechanisms, and the potential use of biologics to modulate these mechanisms. REVIEW FINDINGS: The inflammatory response in COPD includes both type 1 and type 2 immune cells. Type 2 inflammation is suggested by eosinophilia in a significant proportion of patients with COPD. Studies targeting IL-5 in patients with COPD have failed to demonstrate significant reductions in exacerbations, suggesting that eosinophil modulation alone may be insufficient to treat COPD. Based on a better understanding of the disease and role of alarmins, with a broader role in the inflammatory cascade, it is likely that some biologics may benefit certain COPD endotypes. Ongoing trials will provide information about which groups can benefit from the blocking of specific pathways (eg, IL-5, IL-4/IL-13, IL-33, thymic stromal lymphopoietin). SUMMARY: Biologics targeting inflammatory pathways may be effective treatments for specific patients with COPD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Celli, Anzueto, Singh, et al. The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD. Chest. 2024. PMID: 39631681. doi:10.1016/j.chest.2024.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。